However, SAR131675, a novel VEGFR3-specific tyrosine kinase inhibitor, has been shown to reduce primary tumor growth as well as lymph node and lung metastasis through the inhibition of lymphangiogenesis and tumor-associated macrophages invasion [96]. Here, FLT4 is linked to neoplasm.